Avac Event
On Thursday, May 16, Mary Marovich, the Director of the Vaccine Research Program at the Division of AIDS at the National Institute of Allergy and Infectious Diseases, and long-time HIV vaccine research advocate and community leader, Mark Hubbard, provided their perspectives on the current vaccine landscape, the advocacy priorities and what should be on all of our minds as this exciting science progresses.
Recording: YouTube / Audio / Introductory Slides / Mary Marovich’s Slides
Avac Event
On Thursday, May 23, Heidi Larson, the Director of The Vaccine Confidence Project at the London School of Tropical Medicine and Hygiene discussed vaccine hesitancy and its implications across global health. We were also joined by Laura Lopez Gonzalez, deputy editor of South Africa’s Bhekisisa Health Journalism Centre, who shared perspectives on broader vaccine issues, especially as they play out in the media and affect the AIDS response.
Avac Event
On Thursday, October 26, colleagues from the Treatment Action Group (TAG), along with advocates, researchers and GPP practitioners, discussed the recommendations from TAG’s recently released white paper, HIV Research in the Era of PrEP: The Implications of TDF/FTC for Biomedical Prevention Trials.
The effectiveness and increasing availability of oral PrEP raises questions about how it should be incorporated into clinical trial designs for next-generation HIV prevention options. This paper explores ethics, the scientific literature to date, and advocates’ views on the issue.
Avac Event
AVAC PxROAR Europe presents a webinar introducing European approaches to HIV vaccines and a cure:
Both EHVA and HIVACAR are funded by the European Union’s Horizon 2020 Research and Innovation Programme.
Recording: YouTube / Audio / EHVA Slides / HIVACAR Slides
Avac Event
On Thursday, May 17, AVAC’s HVAD 2018 webinar told the story of the current state of HIV vaccine research from two perspectives. Dr. Sandhya Vasan of the Military HIV Research Program in Thailand provided her perspectives on the world of HIV vaccine research since RV144: where have we come and where are we going? Mark Hubbard, a veteran vaccine advocate and community representative for HIV research in Nashville, Tennessee offered his take from a community and advocacy perspective: what are today’s current successes and challenges, and how are community members pushing the HIV vaccine agenda?
Recording: YouTube / Audio / Dr. Sandhya Vasan’s Slides / Mark Hubbard’s Slides
Avac Event
This year marks the 20th anniversary of HIV Vaccine Awareness Day (HVAD). As HIV prevention advocates, we find ourselves in new terrain when it comes to vaccine research—both in terms of scientific progress and the challenging political environment. We highlight these important issues in an HVAD webinar series leading up to and ending on May 18.
Recordings of the webinars available here:
Avac Event
The HIV Vaccine Awareness Day 2017 webinar series kicked off with an overview of the Ad26/mosaic vaccine efficacy program from Janssen’s Maria Grazia Pau. This strategy is notable both for the science and for the active leadership from industry. Dr. Pau did a terrific job of explaining where the strategy fits into the broader vaccine field.
Recording Available: YouTube / Audio / Slides
This was one in a series of HIV Vaccine Awareness Day webinars. For details on all other calls, including recordings, visit here.
Avac Event
Long-time vaccine researcher Barney Graham presented an excellent overview of the history and work of NIH’s Vaccine Research Center (VRC)—established two decades ago on the inaugural HIV Vaccine Awareness Day (HVAD) in 1997. Download the recording for an accessible overview of the HIV vaccine field, the connections between the work on HIV and other vaccines at the VRC and tips on what advocates and researchers should be calling for this HVAD.
Recording Available: YouTube / Audio / Slides
This was one in a series of HIV Vaccine Awareness Day webinars. For details on all other calls, including recordings, visit here.
Avac Event
Dr. Fatima Laher, protocol co-chair of HVTN 702, provides an overview of the first HIV vaccine efficacy trial in seven years. Her presentation looks at the history, starting with partial success of RV144 in 2009, and talks about the role HVTN 702 as the field advances toward an effective vaccine.
Recording: YouTube / Audio / Slides
This was one in a series of HIV Vaccine Awareness Day webinars. For details on all other calls, including recordings, visit here.
Avac Event
Dr. Lynn Morris, head of HIV Virology at South Africa’s National Institute for Communicable Diseases and professor at the University of the Witwatersrand in Johannesburg, provided an overview of antibody research for HIV prevention. She laid out the current landscape; provided a glimpse of what is to come in this dynamic field; talked about where antibody work fits in the larger field of prevention research; and described how the Antibody Mediated Prevention (AMP) studies – ongoing proof-of-concept trials of the broadly neutralizing antibody VRC01 – might advance HIV prevention.
This was the fourth in our series of HIV Vaccine Awareness Day webinars. For details on the full series, visit avac.org/hvad.